vimarsana.com
Home
Live Updates
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating : vimarsana.com
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Related Keywords
United States
,
Janet Graesser
,
Jennifer Zibuda
,
Groupa Strep
,
Exchange Commission
,
Company Potential Pneumococcal Conjugate Vaccine
,
Corporate Communications
,
Nasdaq
,
Drug Administration
,
Sutro Biopharma Inc
,
Vaxcyte Inc
,
Data Monitoring Committee
,
Immunogenicity Data
,
Third Quarter
,
Provide Coverage
,
Coverage Against
,
Grant Pickering
,
Chief Executive Officer
,
Biologics License Application
,
Breakthrough Therapy
,
Sutro Biopharma
,
Private Securities Litigation Reform Act
,
Quarterly Report
,
Vice President
,
Senior Director
,
Investor Relations
,
Nasdaq Pcvx
,
Maxcyte
,
Nc
,
vimarsana.com © 2020. All Rights Reserved.